Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Andrea Viale

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4328-1044; OpenAlex author ID A5075562619; NIH RePORTER profile ID 10590694. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
73
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 1 paper, 1 grant · 2026: 5 papers

Papers 20

  1. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  2. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  3. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  4. GFER Represents a Target for Dual Disruption of Redox Homeostasis and Reactivation of the Immune Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-24-4211↗
  5. DPY30 Is an Epigenetic Decoupler Linking Replication Stress to Immunoediting in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-3849↗
  6. KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-2024↗
  7. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer Co-author DOI 10.1101/2024.10.21.619543↗
  8. Clonal dominance defines metastatic dissemination in pancreatic cancer. Last author DOI 10.1126/sciadv.add9342↗
  9. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer. Co-author DOI 10.1126/sciadv.adk5386↗
  10. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  11. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  12. Clonal Heterogeneity Supports Mitochondrial Metabolism in Pancreatic Cancer Co-author DOI 10.1101/2020.05.15.098368↗
  13. Diversity Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by Network-Anchored Functional Genomics Co-author DOI 10.1101/2020.09.17.302034↗
  14. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Co-author DOI 10.1038/s41586-019-1062-1↗
  15. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/nature21052↗
  16. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  17. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.05.063↗
  18. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. First author DOI 10.1158/0008-5472.can-14-1854↗
  19. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
  20. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/nature13611↗

Grants 1

  1. Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer R01CA258917↗

Closest collaborators

The 25 strongest of 73 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giulio Francesco Draetta · 16 shared papers, 2014–2026 · strength 1.70
  2. Giannicola Genovese · 14 shared papers, 2014–2026 · strength 1.61
  3. Huamin Wang · 13 shared papers, 2014–2026 · strength 1.44
  4. Haoqiang Ying · 13 shared papers, 2014–2026 · strength 1.44
  5. Timothy Paul Heffernan · 14 shared papers, 2014–2026 · strength 1.40
  6. Alessandro Carugo · 12 shared papers, 2014–2026 · strength 1.20
  7. Wantong Yao · 11 shared papers, 2014–2026 · strength 1.17
  8. Ronald Anthony Depinho · 11 shared papers, 2014–2026 · strength 1.05
  9. Virginia Giuliani · 9 shared papers, 2014–2026 · strength 1.03
  10. I-Lin Ho · 7 shared papers, 2019–2026 · strength 0.96
  11. Jason B. Fleming · 10 shared papers, 2014–2026 · strength 0.93
  12. Anirban Maitra · 9 shared papers, 2016–2026 · strength 0.89
  13. Francesca Citron · 5 shared papers, 2024–2026 · strength 0.82
  14. Ziheng Chen · 5 shared papers, 2019–2026 · strength 0.72
  15. Ya’an Kang · 5 shared papers, 2014–2026 · strength 0.53
  16. Prasenjit Dey · 4 shared papers, 2017–2026 · strength 0.49
  17. Tony Gutschner · 4 shared papers, 2017–2026 · strength 0.49
  18. Johnathon Lynn Rose · 5 shared papers, 2016–2026 · strength 0.47
  19. Piergiorgio Pettazzoni · 7 shared papers, 2014–2026 · strength 0.43
  20. Costas Andreas Lyssiotis · 4 shared papers, 2014–2026 · strength 0.42
  21. Avnish Kapoor · 5 shared papers, 2014–2026 · strength 0.35
  22. Luigi Perelli · 2 shared papers, 2024–2026 · strength 0.31
  23. Michael P. Kim · 3 shared papers, 2020–2024 · strength 0.30
  24. Lynda Chin · 4 shared papers, 2014–2026 · strength 0.29
  25. Lifeng Yang · 2 shared papers, 2017–2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.